Antibiotic Treatment for Trunk Cellulitis
For nonpurulent trunk cellulitis, treat with a beta-lactam antibiotic targeting streptococci: cephalexin 500 mg every 6 hours or penicillin-based regimens for 5-10 days. 1
Treatment Algorithm Based on Clinical Presentation
Nonpurulent Cellulitis (No Drainage, No Abscess)
This represents the majority of trunk cellulitis cases. Beta-hemolytic streptococci are the primary pathogens, not MRSA 1, 2, 3.
First-line options:
- Cephalexin 500 mg every 6 hours PO 4
- Cefazolin 0.5-1 g every 8 hours IV (if hospitalized) 4
- Penicillin-based regimens (penicillin VK or amoxicillin)
Duration: 5-10 days, individualized to clinical response 1
Critical point: Even in areas with high community MRSA prevalence, empiric MRSA coverage is NOT recommended for nonpurulent cellulitis 1, 2, 3. Add MRSA coverage only if the patient fails to respond to beta-lactam therapy within 48-72 hours or presents with systemic toxicity 1.
Purulent Cellulitis (Drainage/Exudate Without Drainable Abscess)
MRSA coverage IS required empirically 1.
Outpatient oral options:
- Clindamycin alone (covers both streptococci and MRSA) 1
- TMP-SMX 160-800 mg every 12 hours PLUS amoxicillin (dual coverage) 1
- Doxycycline or minocycline PLUS amoxicillin 1
- Linezolid 600 mg twice daily (covers both, but expensive) 1
Hospitalized/complicated cases:
- Vancomycin 15 mg/kg every 12 hours IV 1
- Linezolid 600 mg twice daily IV/PO 1
- Daptomycin 4 mg/kg/dose IV once daily 1
Duration: 7-14 days for complicated cases 1
Penicillin Allergy Management
For patients with documented penicillin allergy:
- Clindamycin 600 mg IV/PO three times daily (if local resistance <10%) 1
- TMP-SMX 160-800 mg every 12 hours (does NOT cover streptococci—must add coverage if nonpurulent) 1
- Doxycycline/minocycline (same limitation as TMP-SMX) 1
Important caveat: Most penicillin allergies are not true IgE-mediated reactions. Recent evidence suggests cephalosporins can be safely used in most patients with penicillin allergy labels 5. Consider allergy evaluation or direct cephalosporin use if the reaction history is remote or non-severe.
When to Consider MRSA Coverage in Nonpurulent Cellulitis
Add MRSA-active therapy if:
- No clinical improvement after 48-72 hours of beta-lactam therapy 1
- Systemic toxicity present (fever >38.5°C, tachycardia >110 bpm) 1
- High-risk populations: athletes, prisoners, military recruits, MSM, IV drug users, long-term care residents, prior MRSA infection 6
Evidence Strength Discussion
The IDSA guidelines 1 provide the strongest recommendations (A-II level evidence) that nonpurulent cellulitis should target streptococci, not MRSA. This is supported by multiple studies showing beta-lactams remain effective despite rising community MRSA rates 2, 3. The pathogenesis studies indicate streptococci cause most nonpurulent cellulitis, while MRSA predominantly causes purulent infections 2, 6, 3.
Common pitfall: Overuse of MRSA-active antibiotics (clindamycin, TMP-SMX) for typical nonpurulent trunk cellulitis. This increases costs, side effects, and antibiotic resistance without improving outcomes 3, 7.
Surgical Site Infections (Post-Operative Trunk)
If trunk cellulitis is post-surgical: